ACAD

25.69

1.15% -0.30

Handel nachbörslich: 25.69

Acadia Pharmaceuticals Inc (ACAD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ACAD? Forum Prognose

Schlusskurs vom Vortag:

$25.99

Offen:

$25.99

24-Stunden-Volumen:

2.28M

Relative Volume:

1.26

Marktkapitalisierung:

$4.33B

Einnahmen:

$890.53M

Nettoeinkommen (Verlust:

$30.57M

KGV:

142.72

EPS:

0.18

Netto-Cashflow:

$80.53M

1W Leistung:

-0.12%

1M Leistung:

+9.18%

6M Leistung:

+31.07%

1J Leistung:

+54.95%

1-Tages-Spanne:

$25.67

$26.50

1-Wochen-Bereich:

$25.67

$26.65

52-Wochen-Spanne:

$13.40

$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Firmenname

Acadia Pharmaceuticals Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (650)

Telefon

858-558-2871

Adresse

12830 EL CAMINO REAL, SAN DIEGO

Mitarbeiter

654

Twitter

@acadiapharma

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACAD Acadia Pharmaceuticals Inc	25.69	4.38B	890.53M	30.57M	80.53M	0.18
VRTX Vertex Pharmaceuticals Inc	401.00	100.25B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	577.90	61.55B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	447.00	58.53B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	706.41	43.59B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	332.04	33.67B	3.81B	-644.79M	-669.77M	-6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-21	Hochstufung	Deutsche Bank	Hold → Buy
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2025-01-03	Herabstufung	Guggenheim	Buy → Neutral
2024-10-10	Fortgesetzt	Raymond James	Mkt Perform
2024-08-07	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-06-27	Eingeleitet	BMO Capital Markets	Outperform
2024-03-12	Herabstufung	Mizuho	Buy → Neutral
2024-03-12	Bestätigt	Needham	Buy
2024-01-30	Eingeleitet	Robert W. Baird	Outperform
2024-01-24	Hochstufung	Needham	Hold → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Herabstufung	Deutsche Bank	Buy → Hold
2023-12-13	Eingeleitet	Citigroup	Buy
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-11-06	Hochstufung	Mizuho	Neutral → Buy
2023-10-17	Eingeleitet	UBS	Buy
2023-10-10	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-04	Herabstufung	Goldman	Neutral → Sell
2022-11-01	Eingeleitet	Loop Capital	Hold
2022-08-08	Herabstufung	Citigroup	Buy → Neutral
2022-08-05	Herabstufung	Citigroup	Buy → Neutral
2022-06-21	Herabstufung	Jefferies	Buy → Underperform
2022-06-16	Hochstufung	Jefferies	Hold → Buy
2022-03-16	Hochstufung	Canaccord Genuity	Hold → Buy
2022-02-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-01-05	Hochstufung	Citigroup	Neutral → Buy
2021-12-21	Herabstufung	Guggenheim	Buy → Neutral
2021-11-01	Hochstufung	Guggenheim	Neutral → Buy
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-06-10	Eingeleitet	Berenberg	Hold
2021-04-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-04-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-04-06	Herabstufung	Goldman	Buy → Neutral
2021-04-06	Herabstufung	Jefferies	Buy → Hold
2021-04-06	Herabstufung	Mizuho	Buy → Neutral
2021-04-05	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-03-10	Herabstufung	BofA Securities	Buy → Neutral
2021-03-09	Herabstufung	Citigroup	Buy → Neutral
2021-03-09	Herabstufung	Guggenheim	Buy → Neutral
2021-03-09	Bestätigt	H.C. Wainwright	Buy
2021-03-09	Herabstufung	Raymond James	Strong Buy → Outperform
2021-03-09	Herabstufung	Stifel	Buy → Hold
2020-12-16	Eingeleitet	Mizuho	Buy
2020-11-16	Hochstufung	Raymond James	Outperform → Strong Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-08-20	Eingeleitet	Morgan Stanley	Overweight
2020-07-07	Hochstufung	Stifel	Hold → Buy
2020-04-16	Eingeleitet	Jefferies	Buy
2020-03-31	Hochstufung	Goldman	Neutral → Buy
2020-03-06	Eingeleitet	Citigroup	Buy
2019-12-16	Eingeleitet	Guggenheim	Buy
2019-10-24	Eingeleitet	Oppenheimer	Perform
2019-10-01	Eingeleitet	RBC Capital Mkts	Outperform
2019-09-13	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Hochstufung	Canaccord Genuity	Hold → Buy
2019-07-23	Bestätigt	Needham	Buy
2018-12-10	Eingeleitet	Canaccord Genuity	Hold
2018-09-21	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-08-09	Bestätigt	Stifel	Hold
2018-08-07	Eingeleitet	Stifel	Hold
2018-08-06	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

Sep 02, 2025

Is ACADIA Pharmaceuticals Inc. in a consolidation phase2025 Market Outlook & Community Shared Stock Ideas - خودرو بانک

Sep 02, 2025

Analyzing drawdowns of ACADIA Pharmaceuticals Inc. with statistical tools2025 Retail Activity & Stepwise Trade Execution Plans - Newser

Sep 02, 2025

Can ACADIA Pharmaceuticals Inc. sustain its profitabilityJuly 2025 Review & Low Drawdown Investment Strategies - خودرو بانک

Sep 02, 2025

Pattern recognition hints at ACADIA Pharmaceuticals Inc. upsideRate Cut & Verified Momentum Watchlists - Newser

Sep 02, 2025

Sep 01, 2025

ACADIA Pharmaceuticals Inc. stock daily chart insights2025 Historical Comparison & Reliable Trade Execution Plans - Newser

Sep 01, 2025

Aug 31, 2025

Signal strength of ACADIA Pharmaceuticals Inc. stock in tech scannersRate Cut & Fast Entry Momentum Alerts - Newser

Aug 31, 2025

Market reaction to ACADIA Pharmaceuticals Inc.’s recent newsWeekly Trade Report & AI Forecasted Entry and Exit Points - Newser

Aug 31, 2025

How to manage a losing position in ACADIA Pharmaceuticals Inc.Earnings Recap Report & Weekly Watchlist for Consistent Profits - Newser

Aug 31, 2025

Using data models to predict ACADIA Pharmaceuticals Inc. stock movementProduct Launch & Fast Exit and Entry Strategy Plans - Newser

Aug 31, 2025

Does ACADIA Pharmaceuticals Inc. show high probability of rebound2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser

Aug 31, 2025

Aug 30, 2025

What makes ACADIA Pharmaceuticals Inc. stock price move sharplyJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser

Aug 30, 2025

ACADIA Pharmaceuticals Inc. stock volume spike explainedTreasury Yields & Proven Capital Preservation Tips - Newser

Aug 30, 2025

Can machine learning forecast ACADIA Pharmaceuticals Inc. recoveryWeekly Market Report & Low Drawdown Momentum Ideas - Newser

Aug 30, 2025

How to integrate ACADIA Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Gainers & Consistent Growth Equity Picks - Newser

Aug 30, 2025

Sector ETF performance correlation with ACADIA Pharmaceuticals Inc.July 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser

Aug 30, 2025

Institutional scanner results for ACADIA Pharmaceuticals Inc.July 2025 Analyst Calls & Low Risk High Reward Ideas - Newser

Aug 30, 2025

Published on: 2025-08-30 06:46:07 - Newser

Aug 30, 2025

Using portfolio simulators with ACADIA Pharmaceuticals Inc. includedWeekly Trade Recap & Scalable Portfolio Growth Methods - Newser

Aug 30, 2025

Aug 29, 2025

Published on: 2025-08-29 17:29:10 - Newser

Aug 29, 2025

ACADIA Pharmaceuticals Inc. stock chart pattern explained2025 Earnings Surprises & Reliable Entry Point Trade Alerts - Newser

Aug 29, 2025

Chart based exit strategy for ACADIA Pharmaceuticals Inc.Portfolio Gains Summary & Expert Approved Momentum Ideas - Newser

Aug 29, 2025

Risk adjusted return profile for ACADIA Pharmaceuticals Inc. analyzedJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser

Aug 29, 2025